Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: Pooled safety analysis from Phase IIb and III studies

Journal of Viral Hepatitis

Volumn 22, Issue 4, 2015, Pages 366-375

  Manns, Michael P ^a   Fried, M W ^b   Zeuzem, S ^c   Jacobson, I M ^d   Forns, X ^e   Poordad, F ^f   Peeters, M ^g   Fu, M ^g   Lenz, O ^g   Ouwerkerk Mahadevan, S ^h   Jessner, W ^g   Scott, J A ⁱ   Kalmeijer, R ^j   De La Rosa, G ^j   Sinha, R ^g   Beumont Mauviel, M ^g  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

^h JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

ⁱ Janssen Global Services   (United Kingdom)

^j JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

hepatitis C virus; protease inhibitor; safety; simeprevir

Indexed keywords

BILIRUBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; SIMEPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT;

ANEMIA; ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; METAVIR SCORE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SCORING SYSTEM; SIDE EFFECT; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; CLASSIFICATION; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXANTHEMA; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; PATHOLOGY; PREVALENCE; PROCEDURES; PRURITUS; VIROLOGY;

ANEMIA; ANTIVIRAL AGENTS; BILIRUBIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXANTHEMA; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; NEUTROPENIA; PREVALENCE; PRURITUS; RIBAVIRIN; SIMEPREVIR;

EID: 84925446450     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12346     Document Type: Article

References (25)

1. World Health Organization. Hepatitis C fact sheet No. 164, 2013. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed 5th May 2014).
2. Asselah T, Marcellin P,. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32 (Suppl 1): 88-102.
3. Casey LC, Lee WM,. Hepatitis C therapy update. Curr Opin Gastroenterol 2012; 28: 188-192.
4. Manns MP, von Hahn T,. Novel therapies for hepatitis C-one pill fits all? Nat Rev Drug Discov 2013; 12: 595-610.
5. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
6. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
7. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
8. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
9. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887.
10. Reesink HW, Fanning GC, Farha KA, et al,. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138: 913-921.
11. Manns M, Reesink H, Berg T, et al,. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011; 16: 1021-1033.
12. Zeuzem S, Berg T, Gane E, et al,. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a Phase IIb trial. Gastroenterology 2014; 146: 430-441.
13. Moreno C, Berg T, Tanwandee T, et al,. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012; 56: 1247-1253.
14. Fried MW, Buti M, Dore GJ, et al,. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-1929.
15. Tanwar S, Trembling PM, Dusheiko GM,. TMC435 for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2012; 21: 1193-1209.
16. Lawitz E, Sulkowski MS, Ghalib R, et al,. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; Jul 26 [Epub ahead of print].
17. American Association for the Study of Liver Diseases (AASLD). Recommendations for testing, managing, and treating Hepatitis C, 2014. Available at: www.hcvguidelines.org/full-report-view (accessed 5th May 2014).
18. Forns X, Lawitz E, Zeuzem S, et al,. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a Phase 3 trial. Gastroenterology 2014; 146: 1669-1679.
19. Jacobson IM, Dore GJ, Foster GR, et al,. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: the phase 3, randomised, double-blind, placebo-controlled QUEST-1 trial. Lancet 2014; 384: 403-413.
20. Manns M, Marcellin P, Poordad F, et al,. Simeprevir (TMC435) with peginterferon a-2a or a-2b/ribavirin for the treatment of chronic HCV genotype 1 infection in treatment-naive patients: QUEST-2, a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2014; 384: 414-426.
21. World Health Organization. WHO Toxicity Grading Scale for Determining the Severity of Adverse Events. 2003. Available at: http://www.icssc.org/Documents/Resources/AEManual2003AppendicesFebruary-06-2003%20final.pdf (accessed 5th May 2014).
22. Roujeau JC, Mockenhaupt M, Tahan SR, et al,. Telaprevir-related dermatitis. JAMA Dermatol 2013; 149: 152-158.
23. Huisman MT, Snoeys J, Monbaliu J, Martens M, Sekar V, Raoof A,. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Hepatology 2010; 52: 461A.
24. Hezode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-441.
25. Afdhal NH, Reau N, Everson GT, et al,. Safety and efficacy of telaprevir (TVR) or boceprevir (BOC) in patients with chirrosis: interim results of a longitudinal, observational study. Hepatology 2013; 58: 1103A.